• Conavi Medical presented animal study results at TCT 2026 showing its OCTIV hybrid imaging system could acquire interpretable images using saline without iodinated contrast.
• No device-related complications were observed; the findings support further clinical evaluation, particularly for patients at risk of contrast-associated acute kidney injury.
• The FDA-cleared system is now in commercial clinical use, with its first US placement completed and patient cases ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conavi Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030745PRIMZONEFULLFEED9869006) on November 03, 2026, and is solely responsible for the information contained therein.